Biotech Catalysts This Week: 4 Trial Completions, 15 Earnings Reports and 10 New Financings (Nov 15-22, 2026)
This week brings no FDA decision dates but four trial primary completions, including NVS’s PSMA-positive mCRPC study, alongside 15 earnings reports and 10 new financing filings. Last week saw five programs pushed back or discontinued, including LKFT’s GALACELA SLE study and ANRO’s ALTO-300, while eight companies issued new timelines extending into 2027 and 2028.
At a glance: this week no FDA decision dates, 4 Phase 2 or 3 trials reaching primary completion, 15 earnings reports and 10 new financing filings. Last week: 4 timelines pushed back, 1 program discontinued, 8 new timelines announced and 12 key SEC filings.
🔄 What Changed Last Week
Timelines pushed back or discontinued, in the companies’ own words:
- LKFT discontinued GALACELA SLE study with GLPG3667. Before (2026-05-06): “The GALACELA SLE study with GLPG3667 is currently ongoing, and the final Week 48 data are expected in the second quarter of 2026.” Now (2026-11-12): “GLPG3667 discontinuation: Lakefront has completed a rigorous analysis of the competitive landscape and market opportunity.” SEC filing
- ANRO pushed back ALTO-300 from mid-2026 to 1H 2027. Before (2026-03-16): “ALTO-300 and ALTO-100 Ongoing Phase 2b Trials: Enrollment continues in the Phase 2b trial of ALTO-300 in Major Depressive Disorder (MDD), with topline data expected in…” Now (2026-11-10): “Topline data are expected in 1H 2027 for ALTO-300 and mid-2027 for ALTO-100.” SEC filing
- GANX pushed back rexaceract from Q3 2026 to Q1 2027. Before (2026-08-11): “Phase 2 clinical trial of rexaceract in people with Parkinson’s disease expected to begin in Q3 2026.” Now (2026-11-10): “Phase 2 clinical trial of rexaceract in people with Parkinson’s disease expected to begin in Q1 2027.” SEC filing
- ANTX pushed back PV from third quarter of 2026 to by year-end. Before (2026-05-11): “PV is estimated to affect approximately 155,000 people in the U.S. The Company is proceeding through the regulatory process and plans to initiate the Phase 2 clinical…” Now (2026-11-09): “Phase 2 global study of oral epetraborole in PV cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end Startup activities are…” SEC filing
- ZURA pushed back TibuSURE from third quarter of 2026 to H1 2027. Before (2025-11-13): “Topline data are expected in the third quarter of 2026. · TibuSURE (SSc): The Phase 2 clinical trial in adults with SSc continued to advance during the quarter.” Now (2026-11-09): “Anticipated upcoming milestones The Company remains committed to the ongoing TibuSURE study of tibulizumab in systemic sclerosis, with topline data expected in H1 2027,…” SEC filing
All pushed-back and discontinued milestones →
New timelines announced in press releases:
- DYAI, C1-produced RSV and malaria antibodies: in the first quarter of 2027. “Results are anticipated in the first quarter of 2027.” SEC filing
- QNCX, LAM-001: in the first quarter of 2027. “The trial is fully enrolled, and data is anticipated in the first quarter of 2027.” SEC filing
- FBIOP, FB-607: in the second half of 2027. “FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027.” SEC filing
- FBIO, FB-607: in the second half of 2027. “FB-607 is currently being studied in a randomized, placebo-controlled, Phase 2 trial for IBS-D and we expect to release top-line data in the second half of 2027.” SEC filing
- IMUX, vidofludimus calcium (IMU-838): in December 2026. “The company’s lead investigational asset , vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line…” SEC filing
- TRXB, TRB-061: in mid-2027. “Positive Phase 1a results for TRB-061 support proof of mechanism, with topline Phase 1b data in atopic dermatitis expected in mid-2027” SEC filing
- CRIS, CRIS: initial data expected in December 2026. “To date, 12 patients have been enrolled in the study with initial data expected in December 2026.” SEC filing
- NKTR, ZENITH AD: summer of 2028. “Consistent with its prior guidance, the Company expects that this cash balance will extend its cash runway into the third quarter of 2028 past the initial data readouts from the…” SEC filing
Trial status changes on ClinicalTrials.gov:
- TLSA: Phase 2 trial marked completed (2026-11-13). A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Registry
- BHVN: Phase 3 trial marked completed (2026-11-13). Troriluzole in Adult Participants With Spinocerebellar Ataxia Registry
📄 Key SEC Filings Last Week
Filings that can move a stock, each summarized from the filing itself; financing filings are under Dilution Watch below:
- VALN, 2026-11-13 (clinical trial): Valneva reported positive Phase 2 results for its tetravalent Shigella vaccine candidate S4V2. The infant trial showed a favorable safety profile and immune responses, and the CHIM trial met its primary endpoint with a statistically significant reduction in S. sonnei shigellosis versus placebo. SEC filing
- RZLT, 2026-11-13 (clinical trial): Rezolute reported that the primary endpoint of its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism was achieved, with 13 of 16 enrolled participants meeting the responder criterion, 12 of whom also fully discontinued IV glucose. Full topline results are expected by mid-December 2026. SEC filing
- TRAW, 2026-11-12 (clinical trial): Reported final Phase 2a results for ratutrelvir in 92 COVID-19 patients: median time to sustained symptom resolution 13.5 days versus 14.5 days for PAXLOVID, no viral rebound through Day 28, and treatment-related adverse events in 1 of 32 ratutrelvir patients versus 4 of 30 PAXLOVID patients. SEC filing
- PRAX, 2026-11-12 (clinical trial): Praxis held an Investor Day on Nov 12, 2026, and reported an updated ET prevalence of about 9 million U.S. people, with 2 million seeking treatment. Relutrigine open label data showed an 86% seizure reduction from baseline through 18 months. SEC filing
- OBX, 2026-11-12 (clinical trial): Reported Q3 2026 results: cash of $324.4 million as of September 30, 2026, net loss of $50.7 million or $1.23 per share, and runway into 2H 2028. Presented amsoki-cel melanoma data at SITC with a 67% ORR (10 of 15) and median PFS of 8.3 months, and appointed Mark Reisenauer to the Board. SEC filing
- NTHI, 2026-11-13 (regulatory): CEO Amir Heshmatpour bought 80,000 NeOnc shares on the open market on Nov 5, 6 and 9, 2026, for about $269,082 at roughly $3.36 per share. The company also said FDA granted a Type B End-of-Phase meeting for intranasal NEO100 in recurrent IDH-mutant grade 4 astrocytoma, scheduled for early January 2027. SEC filing
- GSK, 2026-11-13 (regulatory): CHMP recommended updating the Bexsero label to include a single booster dose for individuals aged 10 and older previously vaccinated at least two years earlier, based on the Men-B-096 Phase IIIb study of 312 participants, which met its primary endpoint. SEC filing
- KYTX, 2026-11-12 (regulatory): Kyverna completed its BLA submission for miv-cel in stiff person syndrome, seeking priority review. Q3 2026 net loss was $41.9 million ($0.68 per share) with $170.6 million in cash, expected to fund operations into 2028. SEC filing
- LFCR, 2026-11-13 (deal): Proxy for a special meeting on December 23, 2026 to vote on adopting a merger agreement with Lifecore Inc. and Hazel Merger Sub, affiliates of Webster Equity Partners. Holders would receive $6.28 per share in cash plus one contingent value right per share. SEC filing
- OGI, 2026-11-13 (deal): Organigram agreed to acquire Aurora Cannabis under a plan of arrangement valued at about C$561 million, offering C$7.80 per share in cash or 5.8626 Organigram shares, with C$25.2 million and C$38.4 million termination fees. BAT will buy shares for C$187.5 million in a private placement. SEC filing
- VOR, 2026-11-12 (deal): Amended RemeGen license adds RC298, a long-acting dual BAFF/APRIL inhibitor, for $10 million upfront cash and a pre-funded warrant for 2.3 million shares at $0.0001. RemeGen is eligible for up to $300 million in additional development milestones. SEC filing
- QCLS, 2026-11-13 (listing): Q/C Technologies received a Nasdaq notice on November 6, 2026 that its stock failed to keep a $1.00 minimum bid price for 30 consecutive business days. It has until May 5, 2027 to regain compliance, with a possible additional 180 days. SEC filing
🧪 Phase 2 and 3 Trials Reaching Primary Completion
Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.
- ACHV, 2026-11-15 (Phase 3): Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes Registry
- NVS, 2026-11-17 (Phase 2): An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC Registry
- INCY, 2026-11-20 (Phase 2): A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma Registry
- SKYE, 2026-11-20 (Phase 2): Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo Registry
📊 Earnings This Week
- AIM: 2026-11-16 (est. EPS -0.1364)
- NRXP: 2026-11-16 (est. EPS -0.0286)
- ABEO: 2026-11-16 (est. EPS -0.1556)
- ANNX: 2026-11-16 (est. EPS -0.2854)
- MLYS: 2026-11-16 (est. EPS -0.5476)
- SPRO: 2026-11-16 (est. EPS -0.1428)
- BHVN: 2026-11-17 (est. EPS -0.7579)
- CAPR: 2026-11-17 (est. EPS -0.4420)
- MIRM: 2026-11-17 (est. EPS -0.5229)
- MIST: 2026-11-17 (est. EPS -0.2200)
- SPRY: 2026-11-17 (est. EPS -0.3239)
- CELC: 2026-11-18 (est. EPS -1.4623)
- KYTX: 2026-11-18 (est. EPS -0.7038)
- ZURA: 2026-11-18 (est. EPS -0.2091)
- SRRK: 2026-11-18 (est. EPS -0.8589)
📡 Run-up Radar Highlights
Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):
- TECX: Phase 2 primary completion in 9 days, score 78/100
- NTHI: Phase 1/2 primary completion in 15 days, score 71/100
- CRVO: Data readout guided for November 2026, window closes in 15 days, score 71/100
💸 Dilution Watch: New Financing Filings
- DCOY: shelf registration (S-3, 2026-11-13) EDGAR
- INBX: shelf with ATM program up to $150M (S-3ASR, 2026-11-13) EDGAR
- RZLT: underwritten offering (424B5, 2026-11-13) EDGAR
- VOR: private placement (8-K, 2026-11-12) EDGAR
- VIR: shelf registration (S-3ASR, 2026-11-12) EDGAR
- VIR: underwritten offering (424B5, 2026-11-12) EDGAR
- TLPH: shelf registration (S-3, 2026-11-12) EDGAR
- PROK: registered direct offering (424B5, 2026-11-12) EDGAR
- PRME: underwritten offering $125M (424B5, 2026-11-12) EDGAR
- PEPG: underwritten offering $125M (424B5, 2026-11-12) EDGAR
📉 Downside Radar: Trading Far Below a Recent Offering
Of biotech stocks 25% or more below their close on the day of a recent offering, 76% were lower 60 trading days later, median -29% (any biotech on a random day: 53% lower, median -2%). On the radar now:
- SLXN: $1.98, 74% below $7.63, its close on the day of its Sep 29 private placement (new this week)
- BSEM: $1.05, 66% below $3.09, its close on the day of its Sep 30 private placement
- SBFM: $2.70, 60% below $6.76, its close on the day of its Oct 9 registered direct offering
- BIAF: $2.20, 53% below $4.72, its close on the day of its Oct 9 private placement
- GTBP: $3.72, 48% below $7.18, its close on the day of its Sep 21 private placement
- TCRT: $1.63, 46% below $3.03, its close on the day of its Oct 13 private placement
- NMAD: $2.35, 40% below $3.93, its close on the day of its Sep 30 private placement (new this week)
- BKHA: $7.30, 40% below $12.19, its close on the day of its Sep 24 private placement (new this week)
Full Downside Radar and how it was tested →
📉 Downside Radar: Financing Pressure
12 months of cash or less, an ATM program, shelf or S-1 on file and no offering in 90 days. Of biotech stocks in this setup, 41% sold new shares within three months (10% of comparable stocks) and 69% were lower 60 trading days later, median -17%; with 6 months of cash or less, 51% and 73%. Shortest cash first:
- CUE: about 2.6 months of cash (Jun 30 balance sheet), shelf registration filed Mar 16
- MBRX: about 2.8 months of cash (Sep 30 balance sheet), ATM program filed Aug 21
- NNVC: about 4.1 months of cash (Jun 30 balance sheet), ATM program filed Oct 21
- AKTX: about 4.7 months of cash (Sep 30 balance sheet), S-1 registration filed Jan 23
- BHVN: about 5.0 months of cash (Sep 30 balance sheet), shelf registration filed May 4
- TVRD: about 6.3 months of cash (Jun 30 balance sheet), ATM program filed Jul 17 (new this week)
- ARMP: about 7.7 months of cash (Sep 30 balance sheet), ATM program filed Dec 1
- HYPD: about 8.2 months of cash (Jun 30 balance sheet), ATM program filed May 6
The financing-pressure list and how it was tested →
📈 Last Week’s Biggest Gainers
- PEPG +92.89% (volume 42.0x average)
- ESLA +45.40% (volume 2.0x average)
- BSEM +41.35% (volume 6.2x average)
- HUMA +29.61% (volume 2.3x average)
- CRVO +29.20% (volume 22.7x average)
Earlier weekly catalyst recaps →
Track your tickers on the BioRadar dashboard →
This digest is for informational purposes only and is not investment advice. Always do your own research.